Skip to content

Placenta Accreta Spectrum Topographic Classification

Evaluation of Clinical Outcomes and Acceptability of an Anatomical Classification for Placenta Accreta Spectrum, a Multicentric Prospective Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05922397
Enrollment
326
Registered
2023-06-28
Start date
2023-05-21
Completion date
2025-06-01
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Accreta

Keywords

Pregnancy outcomes, Topographic classification, Placenta accreta

Brief summary

The present study is a prospective multicenter study consisting of a cohort of patients with prenatal or intraoperative diagnosis of PAS, evaluating the clinical outcomes of the group of patients found in each category of the topographic classification. In addition, an approach to evaluate the acceptability of this classification among the obstetrician-gynecologists of the participating medical centers will be included.

Detailed description

The aim of this study is to describe the demographic and clinical characteristics of patients with a diagnosis of placenta accreta spectrum, and to determine the correlation between the topographic classification and the clinical outcomes found in the study. Finally, to evaluated whether the proposed classification is accepted by the obstetrician-gynecologists of the participating centers that manage placenta accreta spectrum patients. It is an observational, multicentric study of a prospective cohort, in which data will be obtained from the medical records and other documents in each participating center, which are considered to be of routine use in day-to-day clinical practice. The study of the outcomes proposed in this protocol will be limited to those recorded in the clinical records and will be taken into account until the participant is discharged from the hospital, during which a surgical intervention was performed due to the suspicion or diagnosis of PAS. It is projected that the period of patient enrollment will last 2 years, counting on from the first participant included. The study population is pregnant patients with a diagnosis of placenta accreta spectrum who visits any of the participating medical centers, and also obstetrician-gynecologists working in participating medical centers. The centers invited to participate are hospitals or clinics that already have knowledge in how to apply the surgical staging of PAS, and the topographic classification and have experience using it.

Interventions

None listed

Sponsors

Fundacion Clinica Valle del Lili
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Pregnant woman over 18 years old. * Prenatal diagnosis by ultrasound or MRI of Placenta Accreta Spectrum (PAS), regardless of the suspected degree of severity of the disease. * Case requiring surgical management, either as scheduled or emergent procedure. * Application of the topographic classification of placenta accreta spectrum during laparotomy.

Exclusion criteria

* None.

Design outcomes

Primary

MeasureTime frameDescription
Days of postoperative hospitalizationFrom the day the surgery is performed until the day of discharge or the date of death from any cause, whichever occurs first, evaluated up to 42 days.Number of days the patient was hospitalized from the day of surgery to the day of discharge
Volume of intraoperative blood lossDuring surgerySurgical bleeding calculated in milliliters
Bladder injuryUp to 42 days postpartumNumber of patients who had Bladder injuries
Surgical reinterventionUp to 42 days postpartumNumber of patients who need surgical reoperation after index surgery
Complications associated with vascular interventionsUp to 42 days postpartumThe patient presented thrombosis or other complication during post-surgery associated with vascular interventions.
Maternal death24 monthsDoes the patient die during this study

Countries

Colombia

Contacts

Primary ContactAlbaro J Nieto-Calvache, MD
albaro.nieto@fvl.org.co6023319090
Backup ContactDaniela Sarria-Ortiz, MD
daniela.sarria.or@fvl.org.co6023319090

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026